Danish pharmaceutical giant Novo Nordisk presented new analyses from the STEP UP Phase 3 trial at the European Congress on Obesity (ECO) in Istanbul. Data show that patients who responded early to treatment with a higher dose of Wegovy (semaglutide 7.2 mg) achieved an average weight loss of 27.7 percent after 72 weeks.
In the overall study, body weight decreased by an average of 20.7 percent for patients treated with semaglutide 7.2 mg, compared to 17.5 percent for the 2.4 mg dose and 2.4 percent for the placebo group.
The analysis also indicates that 84 percent of the weight loss with Wegovy was attributable to a reduction in fat mass, while muscle strength and function were preserved. Abdominal fat decreased by over 30 percent according to MRI data.
STEP UP included over 1,400 adults with obesity without type 2 diabetes and compared semaglutide 7.2 mg with 2.4 mg and placebo over 72 weeks. Novo Nordisk stated that the safety and tolerability profile for the 7.2 mg dose was consistent with that of the lower dose.
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (93.7%);
- rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
